Design of a Phase 2, Randomized, Double-blind, Placebo-controlled Trial of BMS-986368, a Fatty Acid Amide Hydrolase/monoacylglycerol Lipase Inhibitor, for Spasticity Treatment in Multiple Sclerosis

Authors
Category Primary study
ConferenceArchives of physical medicine and rehabilitation
Year 2026
This article has no abstract
Epistemonikos ID: 5d3392f63d3af9dcee259d00da27dd4509c488d5
First added on: May 18, 2026